Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: A Gynecologic Oncology Group study
Author:
Publisher
Elsevier BV
Subject
Obstetrics and Gynecology,Oncology
Reference15 articles.
1. Adjuvant therapy in stage I and stage II epithelial ovarian cancer;Young;N. Engl. J. Med.,1990
2. Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin—A Gynecologic Oncology Group study;Young;J. Clin. Oncol.,2003
3. Adjuvant treatment for early epithelial ovarian cancer: results of two randomized clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). GICOG: Gruppo Interregionale Collaborativo in Ginecologia Oncologica;Bolis;Ann. Oncol.,1995
4. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer;McGuire;N. Engl. J. Med.,1996
5. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer;Alberts;J. Clin. Oncol.,1992
Cited by 236 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. British Gynaecological Cancer Society (BGCS) ovarian, tubal and primary peritoneal cancer guidelines: Recommendations for practice update 2024;European Journal of Obstetrics & Gynecology and Reproductive Biology;2024-09
2. International Federation of Gynecology and Obstetrics Endometrial 2023 Is Better For Radiation Oncology Patients;Practical Radiation Oncology;2024-07
3. Endometriosis-Associated Ovarian Cancer: From Molecular Pathologies to Clinical Relevance;International Journal of Molecular Sciences;2024-04-13
4. Outcomes after fertility‐sparing surgery of early‐stage ovarian cancer: A nationwide population‐based study;Cancer Medicine;2024-04
5. Systemic treatment of ovarian cancer;Onkologie;2024-02-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3